Manidipino Teva (Manidipine Dihydrochloride)

Manidipine is indicated for conditions affecting the cardiovascular system where blood pressure control is required.

• Hypertension: reduces systolic and diastolic blood pressure in essential hypertension.
• Isolated systolic hypertension: lowers elevated systolic pressure, especially in older adults.
• Primary hypertension: provides long‑term blood pressure management in patients with newly diagnosed high blood pressure.

• Manidipine selectively blocks L‑type calcium channels in vascular smooth muscle, preventing calcium influx that leads to muscle contraction. This vasodilatory effect decreases peripheral vascular resistance, resulting in a reduction of systemic arterial pressure without significant negative inotropic activity on the heart.

Manidipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Flushing: warmth and redness of the skin, especially on the face.
• Peripheral edema: swelling of ankles or lower legs.
• Dizziness: sensation of light‑headedness, particularly after standing.
• Tachycardia: increased heart rate without other cardiac pathology.
• Nausea: mild gastrointestinal discomfort.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure leading to fainting.
• Myocardial infarction: rare occurrence of heart attack.
• Arrhythmias: abnormal heart rhythms, including ventricular tachycardia.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Allergic reactions: rash, pruritus, or urticaria.
• Angioedema: swelling of lips, tongue, or airway requiring urgent care.

Manidipine should be used with careful clinical monitoring to ensure safety and efficacy.

• Blood pressure monitoring: regularly assess to avoid excessive hypotension.
• Hepatic impairment: adjust use in patients with liver disease.
• Elderly patients: start at lower doses and monitor for dizziness.
• Concomitant antihypertensives: watch for additive blood‑pressure‑lowering effects.
• Discontinuation: do not stop abruptly; taper under medical guidance.
• Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Manidipine can interact with several drug classes, influencing its antihypertensive effect or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels.
• Other potent vasodilators (e.g., nitroglycerin): risk of severe hypotension.
• Grapefruit juice: can elevate drug concentration.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: additive heart‑rate reduction, monitor pulse.

• Diuretics: may enhance antihypertensive effect, watch electrolytes.
• NSAIDs: can blunt antihypertensive response, monitor renal function.